Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the aim of buying high and selling higher, capitalizing on established price movements [1] - The Zacks Momentum Style Score helps define momentum characteristics, with BrightSpring Health Services, Inc. (BTSG) currently holding a Momentum Style Score of A [2] Group 2: Zacks Rank and Performance - BTSG has a Zacks Rank of 1 (Strong Buy), indicating strong potential for outperformance in the market [3] - Stocks rated Zacks Rank 1 and 2 with Style Scores of A or B have historically outperformed the market over the following month [3] Group 3: Price Performance - BTSG shares have increased by 23.35% over the past week, significantly outperforming the Zacks Medical Services industry, which rose by only 0.63% [5] - Over the past month, BTSG's price change is 29.35%, compared to the industry's 0.88% [5] - In the last quarter, BTSG shares increased by 1.99%, and over the past year, they have gained 95.66%, while the S&P 500 has moved -5.75% and 10.63%, respectively [6] Group 4: Trading Volume - BTSG's average 20-day trading volume is 2,067,688 shares, which serves as a bullish indicator when combined with rising stock prices [7] Group 5: Earnings Outlook - Over the past two months, four earnings estimates for BTSG have been revised upwards, with no downward revisions, increasing the consensus estimate from $0.69 to $0.98 [9] - For the next fiscal year, four estimates have also moved upwards without any downward revisions [9] Group 6: Conclusion - Given the strong performance metrics and positive earnings outlook, BTSG is positioned as a 1 (Strong Buy) stock with a Momentum Score of A, making it a compelling investment option [11]

Core Viewpoint - BrightSpring Health Services, Inc. (BTSG) shows potential as a strong investment opportunity due to significant revisions in earnings estimates, indicating an improving earnings outlook [1][11]. Earnings Estimate Revisions - Analysts have become increasingly optimistic about the earnings prospects of BrightSpring Health Services, leading to higher earnings estimates, which are expected to positively impact the stock price [2]. - The consensus earnings estimate for the current quarter has risen to $0.20 per share, reflecting a 100% increase from the previous year [7]. - For the full year, the earnings estimate is projected at $0.98 per share, representing a year-over-year increase of 75% [8]. - Over the past month, the consensus estimate for the current year has increased by 35.24%, with four estimates moving up and no negative revisions [9]. Zacks Rank and Performance - BrightSpring Health Services has achieved a Zacks Rank 1 (Strong Buy), indicating strong potential for outperformance based on favorable estimate revisions [10]. - Historically, stocks with a Zacks Rank 1 have generated an average annual return of +25% since 2008, suggesting a strong correlation between earnings estimate revisions and stock performance [3][10]. Stock Performance - The stock has experienced a 27% gain over the past four weeks, driven by solid estimate revisions and positive earnings growth prospects [11].

Group 1: BrightSpring Health Services, Inc. (BTSG) - BrightSpring Health Services is a home and community-based healthcare services platform with a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings increased by 18.8% over the last 60 days [1] - BrightSpring's shares gained 3.4% over the last three months, while the S&P 500 declined by 7.6% [1] - The company has a Momentum Score of B [1] Group 2: United Bankshares, Inc. (UBSI) - United Bankshares is a financial holding company that primarily provides commercial and retail banking products and services, also holding a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings increased by 2.9% over the last 60 days [2] - United's shares gained 4.7% over the last month, compared to the S&P 500's advance of 2.7% [2] - The company possesses a Momentum Score of A [2]

Group 1 - Momentum investing contrasts with the traditional strategy of "buy low and sell high," focusing instead on "buying high and selling higher" [1] - Identifying the right entry point for fast-moving stocks can be challenging, as they may lose momentum if future growth does not justify their high valuations [1] - A safer investment approach involves targeting bargain stocks that exhibit recent price momentum [2] Group 2 - BrightSpring Health Services, Inc. (BTSG) is highlighted as a strong candidate for investment, showing a four-week price change of 27% [3] - BTSG has gained 6.3% over the past 12 weeks, indicating its ability to deliver positive returns over a longer timeframe [4] - The stock has a beta of 2.06, suggesting it moves 106% higher than the market in either direction, reflecting fast-paced momentum [4] Group 3 - BTSG has a Momentum Score of A, indicating a favorable time to invest based on momentum [5] - The stock has a Zacks Rank 1 (Strong Buy) due to upward revisions in earnings estimates, which attract more investor interest [6] - BTSG is trading at a Price-to-Sales ratio of 0.35, suggesting it is undervalued at 35 cents for each dollar of sales [6] Group 4 - BTSG appears to have significant potential for growth at a fast pace, alongside other stocks that meet the 'Fast-Paced Momentum at a Bargain' criteria [7] - There are over 45 Zacks Premium Screens available to help identify winning stock picks based on various investing styles [8]

Group 1 - BrightSpring Health Services, Inc. (BTSG) has seen the Zacks Consensus Estimate for its current year earnings increasing by 18.8% over the last 60 days [1] - Norwood Financial Corp. (NWFL) has experienced a nearly 4% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Monro, Inc. (MNRO) has had a 2.5% increase in the Zacks Consensus Estimate for its next year earnings over the last 60 days [2] - United Bankshares, Inc. (UBSI) has seen a 5.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Immunocore Holdings plc (IMCR) has experienced a 4.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]

Company Overview - BrightSpring Health Services, Inc. (BTSG) is part of the Medical group, which consists of 1001 companies and currently ranks 5 within the Zacks Sector Rank [2] - The company is classified under the Medical Services industry, which includes 58 individual companies and is ranked 66 in the Zacks Industry Rank [6] Performance Metrics - Year-to-date, BTSG has increased by approximately 28.2%, while the average performance of Medical stocks has declined by 5.5% [4] - The Zacks Consensus Estimate for BTSG's full-year earnings has risen by 0.2% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [4] Comparative Analysis - Another Medical stock, Cencora (COR), has also outperformed the sector with a year-to-date return of 29.4% and a Zacks Rank of 2 (Buy) [5] - Both BrightSpring Health Services, Inc. and Cencora are performing better than their respective industry averages, with the Medical Services industry averaging a loss of 3% this year [6] Investment Outlook - Investors interested in Medical stocks should closely monitor BrightSpring Health Services, Inc. and Cencora for potential continued strong performance [7]

Financial Data and Key Metrics Changes - Total company revenue for Q1 2025 was $2,900,000,000, representing a 26% year-over-year growth [8][26] - Adjusted EBITDA for the company was $131,000,000, growing 28% compared to the same period last year [9][28] - EBITDA margin increased in the quarter despite fewer days in Q1 2025 compared to Q1 2024, which was a leap year [9][28] Business Line Data and Key Metrics Changes - Pharmacy Solutions revenue was $2,500,000,000, achieving 28% growth year-over-year [8][26] - Provider Services revenue was $346,000,000, representing 12% growth compared to the prior year [8][26] - Within Provider Services, home health care revenue grew 21% to $178,000,000, rehab revenue grew 5% to $70,000,000, and personal care revenue grew 3% to $98,000,000 [27][20] Market Data and Key Metrics Changes - Specialty and Infusion business revenue grew 33% year-over-year, with total script volume growth of 20% [13][14] - Home and community pharmacy revenue grew 14%, driven by increased script volumes and new customers [15][26] Company Strategy and Development Direction - The company is focused on high-quality operations and disciplined investments to drive efficiency, with a commitment to delivering coordinated care in home and community settings [7][10] - A planned divestiture of the Community Living business is expected to close in the second half of 2025, which will be reported in discontinued operations [7][8] - The company expects to continue its growth trajectory, with a mid-teens revenue and EBITDA CAGR over the past nine years [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain growth despite potential regulatory changes, including the IRA [39][42] - The company anticipates strong demand for its services, supported by loyal referral sources and new market investments [10][19] - Management expects to deliver over $300,000,000 of annual run rate operating cash flows in 2025, with a focus on improving leverage ratios [31][32] Other Important Information - The company has a robust pipeline of generic drug launches, with expectations for 16 to 18 additional launches over the next 12 to 18 months [15] - Approximately 50% of the company's drug supply comes from the U.S. and North America, mitigating potential impacts from future pharma tariffs [17][18] Q&A Session Summary Question: What drove the strong gross profit per script in the quarter? - Management indicated that the increase was due to a favorable mix of drugs and proactive purchasing efforts [36] Question: How does the IRA impact pharmacy trends for the second half of the year? - Management stated that they do not foresee any significant changes in pharmacy growth rates due to the IRA [38][42] Question: Can you provide an update on the Amedisys acquisition? - Management noted that they are subject to confidentiality and could not provide specific details but emphasized their quality and platform strength [54] Question: What are the potential scenarios around tariffs? - Management explained that any potential tariff impacts would likely be manageable and that reimbursement for brand drugs is tied to cost [60] Question: How does the infusion business growth outlook look? - Management expressed optimism about the infusion market and indicated they are on pace to meet internal growth budgets [92] Question: What is the guidance update for 2025? - Management increased revenue guidance to $12,000,000,000 to $12,500,000,000 and adjusted EBITDA guidance to $570,000,000 to $585,000,000 [32][33]

Financial Data and Key Metrics Changes - Total company revenue for Q1 2025 was $2.9 billion, representing a 26% year-over-year growth [7][27] - Pharmacy solutions revenue was $2.5 billion, achieving 28% growth year-over-year [7][27] - Provider services revenue was $346 million, reflecting a 12% growth compared to the prior year [7][27] - Adjusted EBITDA for the company was $131 million, growing 28% year-over-year [7][29] - Adjusted EBITDA margin improved despite calendar dynamics, with a negative impact from fewer days in Q1 2025 compared to Q1 2024 [9][29] Business Line Data and Key Metrics Changes - In the pharmacy segment, total revenue grew 28% in Q1, with adjusted EBITDA increasing by 31% [13][30] - Specialty and infusion business revenue grew 33% year-over-year, driven by new drug launches [13][30] - Home health care revenue grew 21% year-over-year, while rehab revenue increased by 5% and personal care revenue grew by 3% [20][28] Market Data and Key Metrics Changes - The company continues to see strong demand for home and community-based health services, with a focus on high-quality care [10][19] - The company has maintained a mid-teens revenue and EBITDA CAGR over the past nine years, indicating consistent growth [19] Company Strategy and Development Direction - The company is focused on leveraging its scale and investing in operational efficiencies to drive growth [6][10] - A planned divestiture of the Community Living business is expected to close in the second half of 2025, which will be reported in discontinued operations [6][7] - The company is optimistic about growth opportunities in pharmacy and provider businesses, particularly in assisted living and behavioral health [25][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth despite potential regulatory changes, including the IRA [38][42] - The company expects to deliver over $300 million in annual operating cash flows in 2025, with a focus on improving leverage ratios [31][32] - Management remains optimistic about the infusion business and its growth potential [90] Other Important Information - The company has a robust pipeline for generic drug launches, which is expected to enhance profitability [51] - Approximately 50% of the company's drug supply comes from the U.S. and North America, mitigating potential tariff impacts [17][19] Q&A Session Summary Question: What drove the strong gross profit per script in the quarter? - Management attributed the increase to a favorable mix of drugs and proactive purchasing efforts [35] Question: How does the IRA impact pharmacy growth in the second half of the year? - Management does not foresee a significant impact from the IRA on pharmacy growth rates [38][42] Question: Can you provide an update on the Amedisys acquisition? - Management stated that they are subject to confidentiality and cannot disclose details but emphasized their strong platform and lack of geographical overlap [54] Question: What are the potential scenarios around tariffs? - Management indicated that there are currently no meaningful tariffs in place and that any potential increases would be manageable [58][60] Question: Is the Amedisys deal indicative of more M&A activity? - Management confirmed that the deal aligns with their acquisition philosophy and does not impact leverage goals [66][68] Question: What is the guidance update for 2025? - Management increased revenue guidance to $12 billion to $12.5 billion, reflecting strong pharmacy performance [32][33]

BrightSpring Health Services, Inc. (BTSG) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 137.50%. A quarter ago, it was expected that this company would post earnings of $0.19 per share when it actually produced earnings of $0.22, delivering a surprise of 15.79%.Over the last four qu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41938 BrightSpring Health Services, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 82-2956404 | | --- | --- | | (State or other jurisdiction of | (I. ...